[Articles] Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

January, 01, 2024 | Select Oncology Journal Articles

225Ac-PSMA RLT shows a substantial antitumour effect in mCRPC and represents a viable therapy option in patients treated with previous lines of approved agents. Xerostomia is a common side-effect. Severe bone marrow and renal toxicity are less common adverse events.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy